Carcinogenesis, Vol. 20, No. 7, 1351-1356,
July 1999
© 1999 Oxford University Press
Carcinogenesis |
Tamoxifen induces G:C
T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene
MRC Toxicology Unit, Hodgkin Building, University of Leicester, PO Box 138, Lancaster Road, Leicester LE1 9HN, UK
Tamoxifen, a rat liver carcinogen, can induce mutations in the lacI gene in the livers of lambda/lacI transgenic rats. However, the presence of persistent tamoxifen adducts on the liver DNA raises the possibility that some contribution to the mutagenesis from ex vivo mutations during the in vitro lacI assay cannot be ruled out. To address this issue, mutagenesis at the cII gene of the transgenic shuttle vector was determined using a selection based assay which is unaffected by the presence of tamoxifen–DNA adducts. Female lambda/lacI transgenic rats were dosed orally with tamoxifen (20 mg/kg body wt) daily for 6 weeks, causing a 3.2-fold increase in the mutant frequency (MF) in the cII gene compared with that obtained with solvent treated animals. This was similar to the MF found previously at the lacI gene and confirms that tamoxifen is mutagenic in vivo. The major class of mutation induced by tamoxifen in the cII gene was G:C
T:A transversions as was found previously in the lacI gene. However, in the one unreplicated study of mutations in the p53 gene of liver tumours induced by tamoxifen, no G:CT:A transversions were found; possible differences between mutagenesis in normal and tumour tissues are explored. The major proportion of the G:CT:A transversions occurred at 5'-CpG-3' dinucleotide (CpG) sites in the lacI gene, but not at such sites in the cII gene. The methylation of CpG sites greatly enhances the targeting of deoxyguanosine by carcinogens, thus this finding might be explained by differences in the methylation patterns at their respective CpG sites; however, nothing is known about the methylation status of either the lacI nor the cII gene in this transgenic rat. This study raises the important issue of which target genes (mammalian or transgenic) should be used as endpoints in mammalian mutagenesis assays.
Abbreviations: CpG, 5'-CpG-3' dinucleotide; MF, mutant frequency.
1 To whom correspondence should be addressed Email: jas12{at}le.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D.-H. Lee and G. P. Pfeifer Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells Mutagenesis, January 1, 2007; 22(1): 63 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Kim, N. Suzuki, Y. R. S. Laxmi, and S. Shibutani INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE Drug Metab. Dispos., February 1, 2006; 34(2): 311 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Besaratinia and G. P. Pfeifer Genotoxicity of Acrylamide and Glycidamide J Natl Cancer Inst, July 7, 2004; 96(13): 1023 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Boyiri, J. Guttenplan, M. Khmelnitsky, W. Kosinska, J.-M. Lin, D. Desai, S. Amin, B. Pittman, and K. El-Bayoumy Mammary carcinogenesis and molecular analysis of in vivo cII gene mutations in the mammary tissue of female transgenic rats treated with the environmental pollutant 6-nitrochrysene Carcinogenesis, April 1, 2004; 25(4): 637 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Besaratinia and G. P. Pfeifer Enhancement of the Mutagenicity of Benzo(a)pyrene Diol Epoxide by a Nonmutagenic Dose of Ultraviolet A Radiation Cancer Res., December 15, 2003; 63(24): 8708 - 8716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Besaratinia and G. P. Pfeifer Weak Yet Distinct Mutagenicity of Acrylamide in Mammalian Cells J Natl Cancer Inst, June 18, 2003; 95(12): 889 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, G. Gamboa da Costa, M.M. Marques, S. D. Shelton, F. A. Beland, and M. G. Manjanatha Mutations induced by {alpha}-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats Carcinogenesis, October 1, 2002; 23(10): 1751 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Besaratinia, S. E. Bates, and G. P. Pfeifer Mutational Signature of the Proximate Bladder Carcinogen N-Hydroxy-4-acetylaminobiphenyl: Inconsistency with the p53 Mutational Spectrum in Bladder Cancer Cancer Res., August 1, 2002; 62(15): 4331 - 4338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Davies, B. Clothier, and A. G. Smith Mutation frequency in the lacI gene of liver DNA from lambda/lacI transgenic mice following the interaction of PCBs with iron causing hepatic cancer and porphyria Mutagenesis, September 1, 2000; 15(5): 379 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction Cancer Res., June 1, 2000; 60(11): 2887 - 2891. [Abstract] [Full Text] [PDF]
|
|